Back to today’s briefing

Story perspectives

Revolutionary CAR-NK Therapy Shows Promise for AML Remission

4/29/2025

33 6

Summary

Story summary

In a groundbreaking Phase I trial, SENTI-202, a CAR-NK therapy for acute myeloid leukemia (AML), has shown remarkable promise. Out of nine patients, four achieved complete remission after other treatments fell short. This innovative therapy selectively targets AML cells, preserving healthy ones, and tackles the complexities of this challenging disease. Exciting further studies are underway to assess its full potential.

1 of 1

Story summary

In a groundbreaking Phase I trial, SENTI-202, a CAR-NK therapy for acute myeloid leukemia (AML), has shown remarkable promise. Out of nine patients, four achieved complete remission after other treatments fell short. This innovative therapy selectively targets AML cells, preserving healthy ones, and tackles the complexities of this challenging disease. Exciting further studies are underway to assess its full potential.